Pf 3922 - 1271119

3 posts / 0 new
Last post
stacrober2
Pf 3922 - 1271119

What information is there on this study as the next line of treatment with ALK nsclc Alectinib resistantance.

catdander
Hi stacrober2, Welcome to

Hi stacrober2, Welcome to Grace. I just wanted to let you know I'll be looking for the long answer for you but unfortunately the short answer is there are no fda approved 3rd gen ALK inhibitors and the trial drugs are still being evaluated. If you are able to access one of them on trial it may be a good next step.

Immunotherapy, nivolumab is an option as well.

All best,
Janine

catdander
Hi stacrober2,

Hi stacrober2,

I sure you have this info but wanted to share anyway. This is the link to the trial testing Pf 3922,
https://clinicaltrials.gov/ct2/show/study/NCT01970865?term=PF-+06463922&...

From May 2015 the following describes the preliminary data on the drug pf 3922. So it does look promising but that's all that can be said at this time. While alimta may be a good next choice 3922 shouldn't be eliminated from the choices if a trial is open in your area.
"PF-3922 Phase 1 trial
Posted on May 16, 2015 by admin
Abstract # 8018 is about a Phase 1 study of PF- 06463922 (3922). 22 patients were studied (18 ALK+ & 4 ROS1+). 17 had central nervous system (CNS) metastases and 19 had prior ALK inhibitor treatment (either 1 or 2).

"Of 15 patients evaluated for efficacy 40% had partial responses. While this is lower than a few of the second generation of ALK inhibitors, remember this is a third generation inhibitor where patients may have had two previous ALK inhibitors." http://alkinhibitors.com/?p=290352

Best of luck,
Janine